Pliant Therapeutics, Inc. (PLRX)

Market Cap	76.77M +2.3%
Revenue (ttm)	n/a
Net Income	-149.34M
EPS	-2.43
Shares Out	61.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	339,036
Open	1.260
Previous Close	1.260
Day's Range	1.225 - 1.275
52-Week Range	1.090 - 1.950
Beta	1.24
Analysts	Hold
Price Target	2.67 (+115.32%)
Earnings Date	May 6, 2026

About PLRX

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Analyst Summary

According to 4 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $2.67, which is an increase of 115.32% from the latest price.

Price Target

$2.67

(115.32% upside)

Analyst Consensus: Hold